Tekla Capital Management LLC trimmed its position in Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) by 28.0% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,837,573 shares of the biotechnology company’s stock after selling 1,102,511 shares during the quarter. Tekla Capital Management LLC owned approximately 6.54% of Pieris Pharmaceuticals worth $14,358,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Creative Planning increased its holdings in shares of Pieris Pharmaceuticals by 8.3% in the 2nd quarter. Creative Planning now owns 65,000 shares of the biotechnology company’s stock valued at $329,000 after acquiring an additional 5,000 shares during the last quarter. Voya Investment Management LLC bought a new stake in shares of Pieris Pharmaceuticals in the 2nd quarter valued at approximately $100,000. State of Wisconsin Investment Board bought a new stake in shares of Pieris Pharmaceuticals in the 2nd quarter valued at approximately $132,000. Acadian Asset Management LLC bought a new stake in shares of Pieris Pharmaceuticals in the 2nd quarter valued at approximately $162,000. Finally, Rhumbline Advisers bought a new stake in shares of Pieris Pharmaceuticals in the 2nd quarter valued at approximately $184,000. Institutional investors and hedge funds own 50.50% of the company’s stock.

A number of equities research analysts have recently weighed in on the company. BidaskClub downgraded Pieris Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 26th. HC Wainwright set a $9.00 price objective on Pieris Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, August 11th. Finally, TheStreet lowered Pieris Pharmaceuticals from a “c-” rating to a “d-” rating in a research report on Monday, June 12th. Five research analysts have rated the stock with a buy rating, The company presently has an average rating of “Buy” and a consensus price target of $8.25.

In related news, Director James A. Geraghty bought 10,000 shares of the company’s stock in a transaction dated Thursday, August 17th. The stock was acquired at an average cost of $4.82 per share, with a total value of $48,200.00. Following the acquisition, the director now owns 10,000 shares in the company, valued at approximately $48,200. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Allan Reine bought 65,000 shares of the company’s stock in a transaction dated Thursday, August 17th. The stock was bought at an average cost of $4.82 per share, with a total value of $313,300.00. Following the completion of the acquisition, the insider now owns 45,000 shares in the company, valued at approximately $216,900. The disclosure for this purchase can be found here. Corporate insiders own 4.05% of the company’s stock.

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) traded up 5.2509% on Thursday, reaching $5.7046. The company had a trading volume of 319,094 shares. Pieris Pharmaceuticals, Inc. has a one year low of $1.30 and a one year high of $5.78. The company has a 50-day moving average of $5.39 and a 200 day moving average of $5.39. The stock’s market cap is $252.76 million.

COPYRIGHT VIOLATION NOTICE: “Pieris Pharmaceuticals, Inc. (PIRS) Shares Sold by Tekla Capital Management LLC” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/09/28/pieris-pharmaceuticals-inc-pirs-shares-sold-by-tekla-capital-management-llc.html.

Pieris Pharmaceuticals Profile

Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.

Institutional Ownership by Quarter for Pieris Pharmaceuticals (NASDAQ:PIRS)

Receive News & Stock Ratings for Pieris Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.